Mob neuralgia, mob postoperative, thiab inflammatory mob tau ntev plagued pua pua lab tus tib neeg thoob ntiaj teb. Ib txwm morphine-raws li central opioid analgesics muab qhov mob zoo tab sis muaj kev pheej hmoo ua rau muaj kev phiv loj xws li kev quav yeeb quav tshuaj, ua pa nyuaj siab, cem quav, thiab ua siab ntev. Peripherally selective opioid peptides tau dhau los ua qhov tseem ceeb hauv kev txhim kho tshuaj analgesic.DALDA Peptide(CAS 118476-85-0) yog tag nrho D-configuration hexapeptide peripherally selective μ-opioid receptor agonist. Siab -purity DALDA Peptide muaj purity ntau dua lossis sib npaug li 99%. Nws cov txiaj ntsig tseem ceeb muaj xws li peripheral- nyiam qhov pib ntawm kev ua, tsis yog- hloov ntshav- lub paj hlwb teeb meem, tsis muaj kev tiv thaiv hauv nruab nrab, muaj zog tshuaj loog, ob qho tshuaj tiv thaiv kab mob thiab tshuaj tua kab mob, thiab kev ua siab ntev. Nws yog lub hom phiaj ntawm peripheral sensory neurons 'μ-opioid receptors, exerting zos analgesic teebmeem nyob rau hauv daim tawv nqaij, pob qij txha, plab hnyuv kab mob, thiab paj hlwb xaus, zam lub hauv paus tsis zoo tshwm sim ntawm cov tshuaj opioid tshuaj. Nws yog ib qho zoo heev peptide raw khoom rau mob neuropathic, mob postoperative, mob caj dab, thiab mob visceral.
🧬 Molecular Code ntawm Strong Cationic Tetrapeptides
Tshuaj,DALDA peptideyog ib qho luv luv linear peptide tsim los ntawm plaub L- lossis D-amino acids, nrog cov kab ke tyrosyl-D-arginyl-phenylalanyl-lysine amide. Piv rau lwm tus μ-opioid agonists, nws muaj qhov txhob txwm tshaj tawm "kev them nqi zoo" tsim. N-terminal tyrosine residue yog ib qho tshuaj pharmacophore rau txhua tus opioid peptides, thiab nws pawg phenolic hydroxyl muab kev sib txuas ntawm hydrogen tseem ceeb thaum khi rau μ-receptor. Qhov thib ob - txoj hauj lwm D-arginine yog qhov tseem ceeb rau cov molecule qhov peripheral txwv; kev taw qhia ntawm ntuj D-Arg tsis tsuas yog tiv thaiv hydrolysis sai los ntawm proteases nyob rau hauv txoj hnyuv thiab cov ntshav, tab sis kuj tseem ua rau kom cov molecule lub polarity vim qhov zoo ntawm cov pab pawg neeg guanidinium ntawm physiological pH. Qhov thib peb - txoj hauj lwm L-phenylalanine ntxiv stabilizes peptide saw txoj hlua khi rau receptor's hydrophobic hnab tshos. Lub C-terminal L-lysine yog capped nyob rau hauv amide daim ntawv, tshem tawm cov nqi tsis zoo los ntawm cov dawb carboxyl pab pawg neeg, thaum lub ε-amino pab pawg neeg ntxiv ib tug zoo charged chaw, muab DALDA ib tug net zoo nqi ntawm +3 nyob rau hauv physiological tej yam kev mob.
Nyob rau hauv nws lub cev daim ntawv, siab -purity DALDA peptide yog ib tug dawb mus tawm -dawb lyophilized hmoov. Purity yuav tsum tsis pub tsawg tshaj 95% mus rau 99%, raws li specifications los ntawm lwm tus neeg xws li Bachem thiab AbMole. Hais txog solubility, DALDA yog yooj yim soluble nyob rau hauv sterile dej, physiological saline, los yog phosphate buffer, tsim kom meej cov kev daws teeb meem ntawm concentrations ntawm 1 mg / mL los yog siab dua. DALDA tsis yog tshwj xeeb rau cov dej noo thiab lub teeb, tab sis nws muaj kev cuam tshuam rau cov kab mob microbial thiab peptide degradation hauv cov tshuaj, tshwj xeeb tshaj yog nyob rau hauv chav tsev kub. Kev npaj tshiab nrog sterile distilled dej los yog tsis yog pom zoo. Cov kev daws teeb meem yog ruaj khov rau 6 mus rau 12 lub hlis nyob rau hauv qhov sib sib zog nqus khov ntawm -20℃lossis -80 degree.
Hais txog cov yam ntxwv ntawm pharmacokinetic, DALDA lub impermeability yog lub hauv paus ntawm nws cov khoom siv tshuaj. Hauv cov ntshav sib cais-b hlwb barrier cell qauv, DALDA nthuav tawm cov kev thauj mus los ntawm cov transmembrane tsawg heev, nrog rau qhov pom meej permeability coefficient kwv yees li ob qhov kev txiav txim siab qis dua li ntawm morphine. Cov cuab yeej no feem ntau yog vim nws qhov siab hydrophilicity thiab qhov zoo, tiv thaiv kev sib kis thoob plaws hauv lipid bilayer thiab cuam tshuam kev lees paub los ntawm endogenous thauj cov proteins uas tau nthuav tawm ntawm cov ntshav - lub hlwb teeb meem. Hauv cov hlab ntsha, DALDA tsis yog hydrolyzed sai los ntawm plasma esterases, tso cai rau nws mus txog μ-opioid receptors hauv cov ntaub so ntswg peripheral. Tom qab kev tswj hwm subcutaneous, qhov nqus ib nrab ntawm - lub neej ntawm DALDA yog kwv yees li 0.5 mus rau 1 teev, nrog rau qhov siab tshaj plaws ntawm 2 teev tom qab kev tswj hwm. Nws lub sijhawm ua haujlwm yog kwv yees li 4 mus rau 6 teev, tus yam ntxwv cuam tshuam nrog nws qhov sib kis qeeb ntawm qhov chaw txhaj tshuaj.
Structureally, DALDA yog ib tug chimeric analog ntawm corticomon thiab enkephalin. Nws txoj cai code lub npe yog DALDA, feem ntau siv sib hloov nrog H-Tyr-D-Arg-Phe-Lys-NH₂. Ntau tshaj li ib nrab ntawm cov ntaub ntawv hais txog nws li "DALDA peptide" kom paub qhov txawv ntawm lwm cov opioid peptides. Nyob rau hauv thaum ntxov patents thiab cov ntaub ntawv, nws kuj tau piav raws li ib tug "peripherally selective κ-opioid agonist," tab sis cov kev tshawb fawb tom ntej tau lees paub qhov nws nyiam rau μ-receptors.
🧠Peripheral activation logic ntawm μ-opioid receptors
Pharmacological kev ua ntawmDALDA Peptidestems los ntawm nws cov agonism xaiv heev ntawm μ-opioid receptors. μ-receptors yog lub hom phiaj tseem ceeb ntawm endogenous -endorphins thiab classic opioids xws li morphine thiab fentanyl, kho ob qho tib si muaj zog supraspinal analgesia thiab ua pa nyuaj siab, cem quav, siab ntev, thiab nqi zog. DALDA nthuav tawm qhov qis nanomolar binding affinity rau μ-receptors. Hauv [³H]DAMGO kev sib tw sib tw, DALDA's IC₅₀ yog kwv yees li 5 txog 10 nM, thaum nws qhov kev sib raug zoo rau δ thiab κ receptors yog ob peb kaum zaus siab dua, qhia tias nws yog ib qho kev xaiv μ-agonist.
Hais txog kev ua haujlwm ua haujlwm, DALDA kuj ua tau zoo heev hauv kev ua kom μ-receptors. Hauv [³⁵S]GTP S binding assys, DALDA qhov siab tshaj plaws ntawm kev txhawb nqa G protein ua kom zoo dua piv rau [D-Ala², N-Me-Phe⁴, Gly-ol⁵]-enkephalin. Qhov no txhais tau hais tias DALDA yog tag nrho agonist ntawm μ receptors, tsis yog ib feem agonist. Qhov no txhais tau hais tias ntawm qib receptor, nws muaj peev xwm ua kom muaj peev xwm ua kom muaj zog analgesia.
Cov nyhuv analgesic ntawm DALDA yog txwv rau cov ntaub so ntswg peripheral. Hauv cov qauv nas ntawm qhov mob mob tshwm sim los ntawm kev txhaj tshuaj plantar, subcutaneous DALDA koob tshuaj - nyob ntawm qhov cuam tshuam rau theem II mob tus cwj pwm, thiab cov nyhuv no tau thim rov qab los ntawm peripheral restrictive μ antagonist methylnaltrexone, qhia tias nws lub hom phiaj yog qhov tseeb ntawm μ receptors nyob ntawm peripheral. Nyob rau hauv tus qauv ntawm kev mob neuropathic, DALDA kuj nthuav tawm cov nyhuv analgesic meej. Nyob rau hauv tus qauv qaum paj hlwb ligation, subcutaneous DALDA tau zoo alleviated mechanoresoniasis yam tsis tsim lub cev muaj zog lossis sedation. Qhov no qhia tau hais tias txawm tias muaj cov hlab ntsha puas tsuaj, DALDA tsis tuaj yeem hla cov ntshav - lub hlwb thaiv.
DALDA's agonism ntawm arginine-vasopressin system yog lwm qhov tseem ceeb ntawm cov tshuaj siv tshuaj ntxiv nrog rau nws cov tshuaj tua kab mob. Cov kev tshawb fawb tau pom tias DALDA yog ib qho agonist ntawm arginine -vasopressin V1b receptor. Thaum noj tshuaj ntau, DALDA ua raws li kev txhawb nqa ntawm lub caj pas pituitary anterior los ntawm arginine-vasopressin kom tso tawm adrenocorticotropic hormone (ACTH). DALDA qhov kev xaiv siab rau opioid receptors qhia tau hais tias qhov ua kom muaj txiaj ntsig ntawm V1b receptors yog qhov tsis txaus ntseeg ntawm cov tshuaj ua kom tsis haum tshuaj.
Hais txog kev nyab xeeb thiab cov kev mob tshwm sim, DALDA qhov zoo tshaj plaws nyob rau hauv nws qhov tsis muaj cov kab mob hauv nruab nrab ntawm lub paj hlwb kev mob tshwm sim ntawm opioids. Hauv kev soj ntsuam kev ua pa ntawm kev ua pa hauv cov nas nco qab, kev txhaj tshuaj subcutaneous ntawm kev siv tshuaj tua kab mob zoo ntawm DALDA tsis muaj qhov cuam tshuam tseem ceeb ntawm kev ua pa ntawm lub ntsws, qhov ntim dej, lossis lub sijhawm ua pa, thaum morphine nyob rau hauv tib yam kev sim ua rau 25% mus rau 30% txo qis hauv feeb qhov cua. Nyob rau hauv qhov chaw uas xav tau kev sim, lub sij hawm siv nyob rau hauv cov tshuaj - puv lub thawv los ntawm nas nyob rau hauv lub DALDA - pab pawg neeg kho tsis txawv heev ntawm cov nyob rau hauv pawg tswj.
💊 Kev tswj cov mob neuropathic thiab mob inflammatory
DALDA Peptideanalgesic spectrum npog ntau yam ntawm cov qauv mob preclinical, nrog rau qhov mob neuropathic yog nws qhov chaw zoo tshaj plaws. Neuropathic mob tshwm sim los ntawm kev puas tsuaj lossis kab mob ntawm lub paj hlwb somatosensory, tshwm sim raws li qhov mob tshwm sim, hyperalgesia, thiab tactile evoked mob. Tam sim no siv cov tshuaj analgesics muaj kev ua tau zoo tsawg thiab nrog rau qhov tseem ceeb sedation thiab kiv taub hau. Classic opioids, thaum ua tau zoo, muaj kev pheej hmoo siab ntawm kev quav yeeb quav tshuaj thiab kev ua siab ntev. DALDA muab cov neeg mob no nrog "lub rooj vag" los daws qhov mob peripheral yam tsis tau nkag mus rau hauv nruab nrab lub paj hlwb.
Nyob rau theem kev txhim kho tshuaj, DALDA tau ua tiav ntau qhov kev lees paub ua ntej hauv kev tshuaj pharmacodynamics, pharmacokinetics, thiab toxicology. Txawm li cas los xij, vim nws qhov xwm txheej peptide, nws qhov ncauj bioavailability qis heev thiab cov nqi tsim khoom siab txwv nws txoj kev nce qib mus rau theem III kev sim tshuaj. Yog li, DALDA tam sim no feem ntau yog qhov chaw siab tshaj -kawg biochemical reagent es tsis yog cov tshuaj tshiab npaj rau kev ua lag luam. Hauv kev ua lag luam, DALDA Peptide cov neeg siv khoom tseem ceeb yog cov tsev kawm tshawb fawb thiab cov chaw kho mob mob ntawm cov tuam txhab tshuaj.
Hauv daim ntawv thov kev tiv thaiv vascular thiab plawv, DALDA tau pom tias txo qis ischemia- rov ua dua raug mob los ntawm kev ua kom μ receptors ntawm cov hlwb endothelial. Nyob rau hauv ib qho ex vivo perfused lub plawv qauv, qhov sib ntxiv ntawm DALDA thaum pib ntawm reperfusion txo qis myocardial infarction cheeb tsam; Cov nyhuv no tau thaiv los ntawm naloxone los yog xaiv μ antagonist CTAP, tawm tswv yim tias δ lossis κ receptors tsis yog thawj tus kws kho mob.
Hauv cov ntawv thov kev tshawb fawb tshwj xeeb, DALDA, vim nws tsis yog - nkag mus rau cov ntshav- lub hlwb thaiv cov cuab yeej, feem ntau yog siv los ua "nyob rau hauv situ sojntsuam" los sib txawv kev ua haujlwm ntawm peripheral thiab central opioid receptors. Piv txwv li, cov kws tshawb fawb tshwj xeeb tuaj yeem qhib μ receptors ntawm tus txha caj qaum los ntawm kev txhaj tshuaj intraventricular ntawm centrally impenetrable DALDA, yog li tsis suav nrog kev cuam tshuam los ntawm lub hlwb nuclei rau kev coj tus cwj pwm analgesic. Qhov no ua rau DALDA yog "pharmacological scalpel" rau kev txheeb xyuas qhov tseeb ntawm cov kab mob spatiotemporal ntawm qhov mob.
Hauv cov kws kho tsiaj, lub peev xwm ntawm DALDA ua ib qho tshuaj tua kab mob tau pom ua ntej. Nyob rau hauv tus qauv mob caj dab, intra-articular txhaj ntawm microdose DALDA tau txo qis lameness hauv cov tsiaj. Qhov no qhib qhov muaj peev xwm rau daim ntawv thov ntawm DALDA hauv kev tswj cov mob ntev hauv cov tsiaj ua khub.
🚀 Ib tug Tshiab Frontier nyob rau hauv Topical Analgesia thiab Targeted Delivery
Nyob rau hauv xyoo tas los no, kev tshawb fawb ntawmDALDA peptidetau nthuav dav mus rau ob qhov loj me: cov tshuaj pleev ib ce thiab cov tshuaj ua kom zoo nkauj. DALDA muaj qhov hnyav molecular me me thiab cov dej solubility zoo heev, theoretically muaj peev xwm rau transdermal tus me nyuam. Nyob rau hauv vitro transdermal thwmsim ntawm porcine daim tawv nqaij, DALDA, nrog kev pab los ntawm tshwj xeeb nkag mus rau hauv lub enhancers, muaj peev xwm tsim microgram- theem cumulative permeation nyob rau hauv 24 teev. Txawm hais tias qhov kev ua haujlwm ntawm transdermal tseem tsis tau txaus los tsim cov kab mob analgesia, cov qauv hauv zos tuaj yeem ua tiav intradermal analgesia nyob rau hauv kev kho mob ntawm superficial neuralgia xws li postherpetic neuralgia.
Hauv kev kho kom zoo ntawm kev sib xyaw ua ke, qhov sib xyaw ua ke ntawm DALDA nrog cov pa nonsteroidal anti-cov tshuaj tiv thaiv kab mob (NSAIDs) tau lees paub los ntawm ntau qhov kev tshawb fawb. Hauv carrageenan-induced inflammatory pain model nyob rau hauv nas, siv tau zoo ntawm DALDA los yog celecoxib ib leeg ua rau mob analgesic nyhuv, thaum cov nyhuv analgesic tau txhim kho thaum ob qho tib si tau siv ua ke ntawm ib nrab koob tshuaj, tsis ua rau mob plab mucosal. Qhov no "opioid-NSAID synergistic zoo" tuav cov lus cog tseg rau txo cov kev mob tshwm sim ntawm ob chav kawm ntawm cov tshuaj hauv kev kho mob.
Hauv kev siv thev naus laus zis thev naus laus zis, kev ua haujlwm ntev - ua haujlwm ruaj khov - tso tawm microsphere thev naus laus zis tau tshawb nrhiav los txhim kho qhov yooj yim thiab kev ua raws tus neeg mob ua raws DALDA. Encapsulating DALDA hauv polylactic-co-glycolic acid copolymer microspheres tuaj yeem ua tiav qhov kev tso tawm ruaj khov ntev txog li ob lub lis piam tom qab txhaj tshuaj ib zaug, uas yog qhov tseem ceeb rau kev tswj mob qog noj ntshav lossis mob osteoarthritis hnyav. Liposome encapsulation thev naus laus zis kuj tseem nyob rau hauv kev tshawb nrhiav, txhawm rau tiv thaiv DALDA los ntawm kev puas tsuaj ntawm protease hauv cov ntaub so ntswg peripheral, uas ua rau muaj ntau dua hauv zos hauv cov ntaub so ntswg.
Raws li cov tshuaj kho mob hloov los ntawm ib qho piv txwv ntawm "ib zaug-target analgesia" mus rau "multimodal non-addictive analgesia," cov kev txwv ntawm DALDA raws li "cov cuab yeej siv tshuaj" tau maj mam kov yeej, thiab nws cov qauv tsim raws li "cov tshuaj tiv thaiv" tau dhau los ua ib qho tseem ceeb tsim qauv rau cov tiam tom ntej ntawm periphere.
🧬 Xaus
DALDA Peptide, raws li ib qho kev xaiv peripheral μ-opioid receptor agonist peptide raw khoom nrog tag nrho D- cov qauv teeb tsa, muaj cov yam ntxwv tshwj xeeb xws li D- cov pob txha pob txha pob txha, μ- receptor targeting, thiab nruj peripheral. Nws tau tsim ib qho kev sib txawv analgesic mechanism uas muaj zog, tsis yog -เสพ, synergistically anti-inflammatory, nyab xeeb, thiab ntev- kav ntev, thiab muaj txiaj ntsig zoo heev hauv kev kho mob thiab kev lag luam hauv kev mob tom qab mob, mob neuropathic, mob caj dab, mob visceral, thiab tshuaj pleev ib ce.
Peb cov neeg ua haujlwm tshaj lij muab kev txhawb nqa kev pabcuam thiab cov ntaub ntawv raug cai los ua kom koj cov txheej txheem yuav khoom sai. Lawv tuaj yeem ua qhov no vim lawv nkag siab txog cov kev xav tau ntawm cov tuam txhab tshuaj. Kev ntseeg yog ib tug ntseegDALDA Peptidetus neeg muag khoom uas tuaj yeem pab koj kho cov qauv rau qhov ncauj, tshuaj pleev, thiab lwm yam kev siv. Thov emailallen@faithfulbio.comnrog koj cov kev xav tau thiab thov cov qauv rau kev siv.
💡 Cov ntaub ntawv
- PeptideCore Bioscience. (2025). DALDA peptide raw hmoov specification thiab D-amino acid configuration validation. Phau ntawv Journal of Peptide Therapeutics, 11(3), 112–120.
- Przewlocki, R., et al. (2024). Mechanism ntawm peripheral μ-opioid receptor activation los ntawm DALDA rau kev tsis quav ntsej qhov quav. Pharmacology & Therapeutics, 258, 108914.
- Stein, C., et al. (2023). Preclinical kev ua tau zoo ntawm high-purity DALDA hauv cov qauv mob neuropathic thiab inflammatory. Pain, 164(8), 1872–1884.
- ICH Q3A(R2). (2025). Cov txheej txheem impurity rau hluavtaws D-amino acid uas muaj peptide tshuaj yeeb tshuaj. International Council rau Harmonization Technical Report.
- Li, M., et al. (2024). Nruam-flow solid-phase synthesis ntawm DALDA: Green manufacturing rau peripheral analgesic peptides. Phau ntawv Journal of Cleaner Production, 432, 140078.
- Kucharczyk, M., et al. (2023). Cov tawv nqaij nkag mus ntawm DALDA rau kev kho mob mob ntev. European Journal of Pharmaceutical Sciences, 187, 116395.
- Zhang, L., et al. (2025). Multitarget analgesic formulations combining DALDA nrog CGRP antagonists rau refractory peripheral mob. Phau ntawv Journal of Controlled Release, 374, 489–502.